Indications For Use Use Level of Oxytetracycline lbs. of Pennox 200 Hi-Flo ® per ton Approved by FDA under NADA #138-938 Pennox 200 Hi-Flo® is a registered trademark of Pharmgate Inc. Chickens For Chickens: Control of infectious synovitis caused by Mycoplasma synoviae, control of fowl cholera caused by Pasteurella multocida sensitive to oxytetracycline. (Feed continuously for 7 - 14 days) 100-200 g/ton 0.5 –1.0 Fo...
Oxytetracyline
Type A Medicated Article
Active Drug Ingredients: Oxytetracycline (from oxytetracycline dihydrate base) equivalent to 200 grams Oxytetracycline Hydrochloride/lb.
Ingredients: Oxytetracycline, Calcium Carbonate, Roughage Products and Mineral Oil.
For Use in the Manufacture of Medicated Feeds. Do Not Feed Undiluted.
CAUTION: For use in Dry Feeds ONLY. NOT FOR USE IN LIQUID FEED SUPPLEMENTS
| Indications For Use | Use Level of Oxytetracycline | lbs. of Pennox 200 Hi-Flo® per ton |
|---|---|---|
| Approved by FDA under NADA #138-938 Pennox 200 Hi-Flo® is a registered trademark of Pharmgate Inc. | ||
| Chickens | ||
| For Chickens: Control of infectious synovitis caused by Mycoplasma synoviae, control of fowl cholera caused by Pasteurella multocida sensitive to oxytetracycline. (Feed continuously for 7 - 14 days) | 100-200 g/ton | 0.5 –1.0 |
| For Chickens: Control of chronic respiratory disease (CRD) and air sac infection caused by Mycoplasma gallisepticum and Escherichia coli susceptible to oxytetracycline. (Feed continuously for 7 - 14 days). | 400 g/ton | 2.0 |
| For Broiler Chickens: Reduction of mortality due to air sacculitis (air sac infection) caused by Escherichia coli susceptible to oxytetracycline (Feed continuously for 5 days). | 500 g/ton | 2.5 |
| Withdrawal Periods and Residue Warnings: Do not feed to chickens producing eggs for human consumption. Do not use in low calcium feed containing less than 0.55% dietary calcium. Use in such feeds may result in violative residues. 24 hour withdrawal period at 500 g/ton use level. No withdrawal period is required when used according to labeling at 100-200 g/ton and 400 g/ton use levels. | ||
| Turkeys | ||
| For Turkeys: Control of hexamitiasis caused by Hexamita meleagridis susceptible to oxytetracycline. (Feed continuously for 7 - 14 days). | 100 g/ton | 0.5 |
| For Turkeys: Control of infectious synovitis caused by Mycoplasma synoviae susceptible to oxytetracycline (Feed continuously for 7 - 14 days) | 200g/ton | 1.0 |
| For Turkeys: Control of complicating bacterial organisms associated with bluecomb (transmissible enteritis, coronaviral enteritis) susceptible to oxytetracycline. (Feed continuously for 7 - 14 days) | 25 mg/lb body weight/day | |
| Withdrawal Periods and Residue Warnings: Do not feed to turkeys producing eggs for human consumption. Zero-day withdrawal period. | ||
| Swine | ||
| For Swine: Treatment of bacterial enteritis caused by Escherichia coli and Salmonella choleraesuis susceptible to oxytetracycline and treatment of bacterial pneumonia caused by Pasteurella multocida susceptible to oxytetracycline. (Feed continuously for 7-14 days.) | Feed approximately 400 g/t, varying with body weight and feed consumption to provide 10 mg/lb. body weight/ day | |
| For Breeding Swine: Control and treatment of leptospirosis (reducing the incidence of abortion and shedding of leptospirae) caused by Leptospira pomona susceptible to oxytetracycline. (Feed continuously for 14 days) | Feed approximately 400 g/t, varying with body weight and feed consumption to provide 10 mg/lb. body weight/ day | |
| Withdrawal Periods: Zero-day withdrawal period. | ||
| Calves, Beef Cattle, and Nonlactating Dairy Cattle | ||
| For Growing Cattle (over 400 lbs.): For the reduction of the incidence of liver abscesses. (Use continuously) | 75 mg/head/day | |
| For Cattle: For the prevention and treatment of the early stages of the shipping fever complex. (Feed 3-5 days before and after arrival in feedlots.) | 0.5-2.0g/head/day | |
| For Calves, Beef Cattle, and Nonlactating Dairy Cattle: Treatment of bacterial enteritis caused by Escherichia coli and bacterial pneumonia (shipping fever complex) caused by Pasteurella multocida susceptible to oxytetracycline. (Feed continuously for 7-14 days) | 10 mg/lb. body weight/day | |
| Withdrawal Periods and Residue Warnings: This drug product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. 5-day withdrawal period at 10 mg/lb. body weight/day use level. No withdrawal period is required when used according to labeling at 75 mg/head/day and 0.5-2.0 g/head/day use level. | ||
| Sheep | ||
| For Sheep: Treatment of bacterial enteritis caused by Escherichia coli and bacterial pneumonia caused by Pasteurella multocida susceptible to oxytetracycline. (Feed continuously for 7-14 days) | 10 mg/lb. body weight/day | |
| Withdrawal Periods: 5-day withdrawal period. | ||
| Honey Bees | ||
| Control of American Foulbrood caused by Paenibacillus larvae, and European Foulbrood caused by Melissococcus plutonius susceptible to oxytetracycline. | 200mg/oz (Dusting) 200 mg/5 lb (Syrup) 800 mg/patty (Extender Patty) | |
| See Mixing, Preparation, and Feeding Directions below. | ||
| Mixing Directions for Honey Bees To manufacture a Type B medicated feed containing 20 g/lb of oxytetracycline hydrochloride activity, mix 2.5 lb of Pennox 200 Hi-Flo with 22.5 lb of powdered sugar (for a total of 25 lb.) To manufacture a Type C medicated feed containing 200 mg of oxytetracycline hydrochloride activity per oz (dusting Type C medicated feed), mix 3.5 lb of Pennox 200 Hi-Flo with 214.5 lb of powdered sugar (for a total of 218 lb). The resulting Type C medicated feed is fed as-is for dusting, or is used to prepare syrup and extender patty feeds. Feeding Directions for Dusting: Dusting: Apply 1 oz (200 mg oxytetracycline) of the dusting Type C medicated feed per colony every 4 to 5 days for a total of 3 applications. Apply the dust on the outer parts or ends of the frames. Caution: Dusting of uncapped brood cells has been reported to cause death of larval honey bees. Do not dust uncapped brood cells. Preparation and Feeding Directions for Syrup: Preparation: First dissolve 1 oz (200 mg oxytetracycline) of the dusting Type C medicated feed in a small quantity of water, then mix into 5 lb of 1:1 sugar syrup (equal parts sugar and water, w/w). Feeding: Feed 5 lb of syrup (200 mg oxytetracycline) per colony every 4 to 5 days for a total of 3 applications. Bulk feed the syrup using feeder pails, or division board feeders, or by filling the combs. Prepare fresh syrup for each application. Preparation and Feeding Directions for Extender Patty: Preparation: Make one patty by mixing 4 oz (800 mg oxytetracycline) of the dusting Type C medicated feed with 5.8 oz (165 g) of vegetable shortening and 11.6 oz (330 g) of sugar. Feeding: Place one patty per colony on the top bars of the brood nest frames in a single application. Warnings: Withdrawal Periods and Residue Warnings: Remove at least 6 weeks prior to main honey flow. Type C medicated feeds should be fed in the spring or fall and consumed by the bees before main honey flow begins to avoid contamination of production honey. Honey stored during medication periods in combs for surplus honey should be removed following final medication of the bee colony and must not be used for human food. Warning: Do not use in a manner contrary to state apiary laws and regulations. Each state has specific regulations relative to disease control and medication. Contact the appropriate official or state departments of agriculture for specific inter- and intrastate laws and regulations. | ||
Marketed by:
Pharmgate Animal Health, LLC
14040 Industrial Road
Omaha, NE 68144
Take Time
Pennox 200 Hi-Flo®
Oxytetracycline
Type A Medicated Article
CAUTION: Federal law restricts medicated feed containing this
veterinary feed directive (VFD) drug to use by or on the order of a
licensed veterinarian.
See mixing directions, claims, cautions and warnings on back.
Restricted Drug (California) - Use Only as Directed.
Not For Human Use.
Net wt. 50 LB (22.68 Kg)
Pharmgate
ANIMAL HEALTH
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Oxytetracycline | ACTIVE INGREDIENT | X20I9EN955 | 1 | |
| Oxytetracycline Anhydrous | ACTIVE MOIETY | SLF0D9077S | 1 | |
| Calcium Carbonate | INACTIVE INGREDIENT | H0G9379FGK | 1 | |
| Mineral Oil | INACTIVE INGREDIENT | T5L8T28FGP | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 51429-202 | 51429-202-02 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Oxytetracycline | X20I9EN955 | ACTIB |
| Calcium Carbonate | H0G9379FGK | IACT |
| Mineral Oil | T5L8T28FGP | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SOAP / TOPICAL | 0.82 %w/w | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | PASTE / TOPICAL | 47.5 %w/w | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | TABLET, FILM COATED / ORAL | NA | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | TABLET, DELAYED RELEASE / ORAL | 5.67 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | POWDER, DENTIFRICE / DENTAL | 0.5 mg/mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | CREAM / TOPICAL | 2772 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | TABLET, DELAYED RELEASE / ORAL | 8.4 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SYSTEM / TOPICAL | 654.36 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | SOLUTION / AURICULAR (OTIC) | 0.38 %w/w | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | TABLET, COATED / ORAL | 1.5 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | TABLET, CHEWABLE / ORAL | 1650 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | LOTION / TOPICAL | 1428 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | OINTMENT / AURICULAR (OTIC) | NA | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | PASTE / DENTAL | 95 %w/w | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | TABLET, EXTENDED RELEASE / ORAL | NA | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | CAPSULE / ORAL | 120 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | FILM, SOLUBLE / ORAL | 14 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SUSPENSION / TOPICAL | 82 %w/w | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | TABLET, COATED / ORAL | 64.8 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | OINTMENT / OPHTHALMIC | 59.5 %w/w | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | OINTMENT / TOPICAL | 9938 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SUPPOSITORY / RECTAL | NA | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | TABLET / ORAL | 793 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | FILM / TRANSDERMAL | 11.42 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | CAPSULE / ORAL | 349.9 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | TABLET, FILM COATED / ORAL | 300 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SUSPENSION / OPHTHALMIC | 0.1 %w/w | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | FILM, EXTENDED RELEASE / TRANSDERMAL | 34 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | CAPSULE, DELAYED RELEASE / ORAL | 20 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | SOLUTION / RESPIRATORY (INHALATION) | 4.02 %w/v | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | OIL / TOPICAL | 43.29 %v/v | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SYSTEM / TRANSDERMAL | 6.09 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | TABLET, CHEWABLE / ORAL | 6 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | GUM, CHEWING / BUCCAL | 3492 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | DROPS / ORAL | NA | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SPRAY / TOPICAL | 1379 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | TABLET, EXTENDED RELEASE / ORAL | 229.7 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | TABLET / ORAL | 113.75 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | CREAM / VAGINAL | 402 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SUPPOSITORY / VAGINAL | 30 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SUSPENSION / AURICULAR (OTIC) | 0.5 %w/v | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | SOLUTION / INTRAVENOUS | 4.02 %w/v | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | CAPSULE, EXTENDED RELEASE / ORAL | 4 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | GEL / TOPICAL | 2.5 %w/w |
Adverse event summaries are temporarily unavailable. Other product information remains available.